RxDoctor Payments Data

Janika Wallace, DO

Family Medicine · North East, MDNPI 1255642930

Payments from drug & device makers

$752in general payments, 2019–2025

Across 28 payments — averaging $26.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$272
  • Astellas Pharma US Inc$131
  • Lilly USA, LLC$60
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$57
  • AbbVie$48
  • AstraZeneca$48
  • plus $136 from 5 others

What the payments were for

  • Food & beverage$752100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$752 in reported general payments places this provider in the 60th percentile of 1,193 family medicine providers in Maryland.

See all family medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$9,854
Medicare patients
74
Services billed
103

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin13$18,789
EliquisApixaban11$17,238
XareltoRivaroxaban16$13,753
SymbicortBudesonide/Formoterol Fumarate16$4,254
Atorvastatin Calcium251$2,878
Rosuvastatin Calcium97$1,601
Levothyroxine Sodium122$1,394
Omeprazole99$1,318
Bupropion XlBupropion Hcl31$1,244
Pravastatin Sodium40$1,140
Celecoxib17$1,110
SynthroidLevothyroxine Sodium17$1,047
Metoprolol Succinate84$980
Amlodipine Besylate150$940
Ondansetron Hcl12$921

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$12$17,23811 claims
AstraZenecaSymbicort$48$4,25416 claims
AbbVieSynthroid$48$1,04717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,193 family medicine providers in Maryland.

Other family medicine in North East

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →